Babington Parker, Rajjoub Kenan, Canady Jerome, Siu Alan, Keidar Michael, Sherman Jonathan H
Department of Neurological Surgery, The George Washington University Medical Center, Washington, District of Columbia 20037.
Columbian College of Arts and Sciences, George Washington University, Washington, District of Columbia 20052.
Biointerphases. 2015 Jun 19;10(2):029403. doi: 10.1116/1.4915264.
Cold atmospheric plasma (CAP) is an emerging modality for the treatment of solid tumors. In-vitro experiments have demonstrated that with increasing doses of plasma, tumor cells assays display decreased cell viability. CAP is theorized to induce tumor cells into apoptosis via multiple pathways including reactive oxygen and nitrogen species as well as cell cycle disruption. Studies have shown CAP treatment can decrease mouse model glioblastoma multiforme tumor volume by 56%, increase life span by 60%, and maintain up to 85% viability of normal cells. Emerging evidence suggests that CAP is a viable in-vivo treatment for a number of tumors, including glioblastoma, as it appears to selectively induce tumor cell death while noncancerous cells remain viable.
冷大气等离子体（CAP）是一种新兴的实体肿瘤治疗方式。体外实验表明，随着等离子体剂量的增加，肿瘤细胞检测显示细胞活力下降。理论上，CAP通过多种途径诱导肿瘤细胞凋亡，包括活性氧和氮物种以及细胞周期紊乱。研究表明，CAP治疗可使小鼠多形性胶质母细胞瘤模型的肿瘤体积减少56%，使寿命延长60%，并使正常细胞的存活率保持在85%。新出现的证据表明，CAP是包括胶质母细胞瘤在内的多种肿瘤的一种可行的体内治疗方法，因为它似乎能选择性地诱导肿瘤细胞死亡，而非癌细胞仍保持活力。
